Mitochondrial DNA release and inflammation in mitochondrial disease pathogenesis

Area of Science:

• Mitochondrial biology and immunology
• Genetics and genomics
• Infectious disease and inflammation

Background:

• Primary mitochondrial diseases (PMDs) affect ~1 in 4,300 individuals, with limited treatment options and high mortality.
• Mitochondrial dysfunction is implicated in numerous common disorders, highlighting the need for therapeutic strategies.
• Current genomic diagnostics identify causes in 30-60% of PMDs, but effective treatments remain elusive.

Purpose of the Study:

• To review recent advances in understanding mitochondrial DNA (mtDNA) release mechanisms in PMDs.
• To explore how released mtDNA activates innate immune signaling pathways, such as the cGAS-STING axis.
• To discuss the implications of mtDNA release for PMD pathogenesis, clinical presentation, and therapeutic development.

Main Methods:

• Literature review of recent research on mtDNA release and innate immunity in PMDs.
• Analysis of studies investigating the role of free mtDNA as a damage-associated molecular pattern (DAMP).
• Synthesis of findings on the cGAS-STING pathway activation by extracellular mtDNA.

Main Results:

• Mitochondrial pathologies can lead to the release of mtDNA into the cytosol and extracellular space.
• Free mtDNA acts as a damage-associated molecular pattern (DAMP), activating sterile innate immune responses.
• The role of mtDNA-induced inflammation in PMD phenotypes (worsening vs. compensatory) requires further investigation.

Conclusions:

• mtDNA release and subsequent innate immune activation are critical mechanisms in PMD pathogenesis.
• Circulating mitochondrial material presents a potential biomarker and therapeutic target for PMDs.
• Understanding these pathways may offer insights into common metabolic, inflammatory, and neurodegenerative diseases.